# Modulation of Cytokines and Immune Cells by Plasma Exchange in Patients With Certain Autoimmune Neurological Diseases

**Authors:** Wanquan Xu, Shuting Chai, Gang Liu, Fei Tian, Weibi Chen, Dawei Shan, Yan Zhang

PMC · DOI: 10.1002/iid3.70369 · Immunity, Inflammation and Disease · 2026-03-07

## TL;DR

This study shows that plasma exchange safely reduces harmful immune signals and improves immune cell balance in patients with autoimmune neurological diseases.

## Contribution

The study provides new insights into how plasma exchange modulates immune cells and cytokines in autoimmune neurological disorders.

## Key findings

- Plasma exchange significantly reduced serum and CSF levels of pro-inflammatory cytokines like IL-6 and TNF-α.
- The procedure increased peripheral blood leukocytes, especially neutrophils, and altered lymphocyte subsets.
- Immunoglobulin levels (IgA, IgG, IgM) decreased significantly in both blood and cerebrospinal fluid after treatment.

## Abstract

Therapeutic plasma exchange (TPE) plays a crucial role in the management of autoimmune neurological disorders, although its effects on cytokines and immune cells are not fully understood. This study aimed to investigate the impact of TPE on immune cell subsets, cytokine levels, and immunoglobulins.

A total of 85 patients with certain autoimmune neurological disorders underwent TPE, during which laboratory markers and complications were monitored. Blood and cerebrospinal fluid (CSF) samples were collected before and after TPE to assess changes in immunoglobulins, lymphocyte subsets, and cytokines. Clinical outcomes were evaluated 1 month after the TPE course using the modified Rankin Scale.

Among 408 TPE procedures, complications were mostly mild and manageable, with no fatalities. Peripheral blood leukocyte counts increased significantly, predominantly due to neutrophil elevation. Lymphocyte subset analysis revealed an increase in the proportion of T cells and a decrease in NK cells. Cytokine analysis showed a reduction in serum levels of IL‐6 and TNF‐α, and a decrease in CSF levels of IL‐6, IL‐8, IL‐10, and IFN‐γ. After TPE, immunoglobulin levels (IgA, IgG, and IgM) were significantly lower in both blood and CSF.

TPE is a safe and well‐tolerated procedure for patients with certain autoimmune neurological disorders, potentially promoting recovery by modulating immune cell subsets and clearing pro‐inflammatory cytokines.

## Linked entities

- **Proteins:** IL6 (interleukin 6), TNF (tumor necrosis factor), CXCL8 (C-X-C motif chemokine ligand 8), IL10 (interleukin 10), IFNG (interferon gamma)

## Full-text entities

- **Genes:** PF4 (platelet factor 4) [NCBI Gene 5196] {aka CXCL4, PF-4, SCYB4}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, MOG (myelin oligodendrocyte glycoprotein) [NCBI Gene 4340] {aka BTN6, BTNL11, MOGIG2, NRCLP7}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, GAD2 (glutamate decarboxylase 2) [NCBI Gene 2572] {aka GAD65}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, LGI1 (leucine rich glioma inactivated 1) [NCBI Gene 9211] {aka ADLTE, ADPAEF, ADPEAF, DEE121, EPITEMPIN, EPT}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}
- **Diseases:** circulatory failure (MESH:D012769), neurodegeneration (MESH:D019636), neuroimmune diseases (MESH:D004194), myasthenic crisis (MESH:D020294), CIDP (MESH:D020277), Complications (MESH:D008107), CNS inflammation (MESH:D007249), autoimmune CNS diseases (MESH:D020274), GBS (MESH:D020275), Anti-NMDAR encephalitis (MESH:D060426), mental disorders (MESH:D001523), hyponatremia (MESH:D007010), Neuroinflammation (MESH:D000090862), autoimmune conditions (MESH:D001327), bleeding (MESH:D006470), Intracranial hemorrhage (MESH:D020300), cerebral edema (MESH:D001929), rashes (MESH:D005076), fever (MESH:D005334), hypotension (MESH:D007022), neurological disorders (MESH:D009461), acute disseminated encephalomyelitis (MESH:D004673), thrombosis (MESH:D013927), TPE (MESH:D054219), brain herniation (MESH:D001927), death (MESH:D003643), thrombocytopenia (MESH:D013921), HIT II (MESH:C562865), ischemic stroke (MESH:D002544), myocardial infarction (MESH:D009203), infection (MESH:D007239), encephalitis (MESH:D004660), leukocytosis (MESH:D007964), allergic reactions (MESH:D004342), hypokalemia (MESH:D007008), NMOSD (MESH:D009471), immune dysregulation (OMIM:614878), sepsis (MESH:D018805), MG (MESH:D009157)
- **Chemicals:** saline (MESH:D012965), oxygen (MESH:D010100), methylprednisolone (MESH:D008775), anticholinesterase inhibitors (-), sodium (MESH:D012964), potassium (MESH:D011188), steroids (MESH:D013256), heparin (MESH:D006493)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967252/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12967252/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967252/full.md

---
Source: https://tomesphere.com/paper/PMC12967252